Moneycontrol

Budget 2023Budget 2023
Live: LIVE: Markets Weekly

Sun Pharma to get growth boost with addition of Deuroxolitinib to its speciality portfolio: Analysts

Brokers remain positive about the acquisition and believe in the growth potential of Deuroxolitinib, which is a part of Concert's patent portfolio

January 20, 2023 / 03:46 PM IST
Representational image

Representational image

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Sun Pharma announced the acquisition of US-based Concert Pharma on January 19, in a $576-million deal that is expected to be completed by 1QFY23.

With this acquisition, Sun Pharma has added Deuroxolitinib to its speciality portfolio, which is a Deuterium-modified Analogue of Ruxolitinib, and enhances its offerings in the dermatology space.

Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry. The company has a patent portfolio that includes its lead product candidate deuruxolitinib, an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease, which is in late-stage development.

Brokers remain positive about the acquisition and believe in the growth potential of deuruxolitinib.